The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

Creative Commons License

Warrender-Sparkes M., Spelman T., Izquierdo G., Trojano M., Lugaresi A., Grand'Maison F., ...Daha Fazla

MULTIPLE SCLEROSIS JOURNAL, cilt.22, sa.4, ss.520-532, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 4
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1177/1352458515594041
  • Dergi Adı: MULTIPLE SCLEROSIS JOURNAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.520-532
  • Anahtar Kelimeler: Multiple sclerosis, disease-modifying therapy, fingolimod, medication persistence, MSBase, DISEASE-MODIFYING THERAPIES, INTERFERON-BETA THERAPY, TREATMENT PATTERNS, ADHERENCE, FINGOLIMOD, NATALIZUMAB
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Objective: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS).